BR112012028321A2 - "compostos análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes de quelação de metal, composição farmacêutica e usos dos ditos compostos" - Google Patents

"compostos análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes de quelação de metal, composição farmacêutica e usos dos ditos compostos"

Info

Publication number
BR112012028321A2
BR112012028321A2 BR112012028321A BR112012028321A BR112012028321A2 BR 112012028321 A2 BR112012028321 A2 BR 112012028321A2 BR 112012028321 A BR112012028321 A BR 112012028321A BR 112012028321 A BR112012028321 A BR 112012028321A BR 112012028321 A2 BR112012028321 A2 BR 112012028321A2
Authority
BR
Brazil
Prior art keywords
desazadesferrotiocin
compounds
chelating agents
metal chelating
pharmaceutical composition
Prior art date
Application number
BR112012028321A
Other languages
English (en)
Inventor
W Malecha James
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Publication of BR112012028321A2 publication Critical patent/BR112012028321A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes quelação de metal. neste documento são divulgados novos compostos de análogos de desazadesferrotiocina poliéter (dadft-pe), assim como composições farmacêuticas compreendendo os mesmos e sua aplicação como agentes de quelação de metal para o tratamento de doença. métodos de quelação de ferro e outros metais em um sujeito humano ou animal também são fornecidos para o tratamento de sobrecarga de metal e toxicidade.
BR112012028321A 2010-05-04 2011-05-04 "compostos análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes de quelação de metal, composição farmacêutica e usos dos ditos compostos" BR112012028321A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33113810P 2010-05-04 2010-05-04
PCT/US2011/035211 WO2011140232A2 (en) 2010-05-04 2011-05-04 Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Publications (1)

Publication Number Publication Date
BR112012028321A2 true BR112012028321A2 (pt) 2017-03-21

Family

ID=44902334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028321A BR112012028321A2 (pt) 2010-05-04 2011-05-04 "compostos análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes de quelação de metal, composição farmacêutica e usos dos ditos compostos"

Country Status (9)

Country Link
US (3) US20130053387A1 (pt)
EP (1) EP2566854A4 (pt)
JP (1) JP2013525495A (pt)
CN (1) CN103038223A (pt)
AU (1) AU2011248158A1 (pt)
BR (1) BR112012028321A2 (pt)
CA (1) CA2798082A1 (pt)
NZ (1) NZ603774A (pt)
WO (1) WO2011140232A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189216B (zh) 2005-04-04 2011-10-19 佛罗里达大学研究基金会 Desferrithiocin聚醚类似物
AU2008229472B2 (en) 2007-03-15 2013-03-14 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
US8063227B2 (en) 2008-07-14 2011-11-22 Ferrokin Biosciences, Inc. Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
WO2011017054A2 (en) * 2009-07-27 2011-02-10 Ferrokin Biosciences, Inc. Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
US8993606B2 (en) 2011-12-09 2015-03-31 Ferrokin Biosciences, Inc. Oral formulations for treating metal overload
KR102111176B1 (ko) 2011-12-16 2020-05-15 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 4'-데스페리티오신 유사체의 용도
US20150299151A1 (en) * 2012-12-07 2015-10-22 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
WO2014122664A1 (en) * 2013-02-11 2014-08-14 Yeda Research And Development Co. Ltd. Lanthanide clusters and methods of use thereof
JP2016513652A (ja) 2013-03-15 2016-05-16 フェロキン バイオサイエンシーズ， インコーポレイテッド デスアザデスフェリチオシン類似体の多形形態
EP3071201A4 (en) 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
AU2016255770A1 (en) * 2015-04-27 2017-11-16 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
CN109862892A (zh) * 2016-08-05 2019-06-07 阿布费罗制药股份有限公司 用于治疗金属介导的病症的给药方案
TWI791362B (zh) 2021-12-27 2023-02-01 財團法人工業技術研究院 有機金屬錯合物、包含其之觸媒組合物、以及聚烯烴的製備方法
CN118561711A (zh) * 2024-07-31 2024-08-30 爱斯特（成都）生物制药股份有限公司 一种制备n-[8-(2-羟基苯甲酰基)氨基]辛酸及其盐的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3002989A1 (de) * 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
US20030022923A1 (en) * 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
AT500490A1 (de) 2001-10-16 2006-01-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte
AU2003263948A1 (en) 2002-08-22 2004-03-11 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20060069134A1 (en) 2002-10-01 2006-03-30 Kaneka Corporation Process for producing optically active alpha-substituted cysteine or salt thereof, intermediate therefor, and process for producing the same
AU2003270473A1 (en) * 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
DE602004014949D1 (de) * 2003-09-09 2008-08-21 Univ Florida Polyamin-metallchelatbildner-konjugate
JP2005289890A (ja) 2004-03-31 2005-10-20 Mitsubishi Pharma Corp ムスカリン性アセチルコリン受容体結合阻害剤
CN101189216B (zh) * 2005-04-04 2011-10-19 佛罗里达大学研究基金会 Desferrithiocin聚醚类似物
US20080093812A1 (en) 2006-05-22 2008-04-24 Ronald Reed Rolling baggage wheels and method for manufacturing the same
US20080138440A1 (en) 2006-11-29 2008-06-12 Cormedix Inc. Methods of diagnosing and alleviating gadolinium toxicity
AU2007351826A1 (en) * 2006-12-12 2008-10-30 University Of Florida Research Foundation, Inc. Desferrithiocin analogue actinide decorporation agents
AU2008229472B2 (en) * 2007-03-15 2013-03-14 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
US8063227B2 (en) 2008-07-14 2011-11-22 Ferrokin Biosciences, Inc. Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
CN101928281A (zh) 2009-06-24 2010-12-29 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
WO2011017054A2 (en) 2009-07-27 2011-02-10 Ferrokin Biosciences, Inc. Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
WO2011028255A2 (en) 2009-08-25 2011-03-10 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof

Also Published As

Publication number Publication date
US9045440B2 (en) 2015-06-02
EP2566854A4 (en) 2013-11-06
CN103038223A (zh) 2013-04-10
CA2798082A1 (en) 2011-11-10
AU2011248158A1 (en) 2012-12-20
NZ603774A (en) 2014-11-28
WO2011140232A2 (en) 2011-11-10
US20150259306A1 (en) 2015-09-17
WO2011140232A3 (en) 2012-02-23
US20110275636A1 (en) 2011-11-10
US20130053387A1 (en) 2013-02-28
EP2566854A2 (en) 2013-03-13
JP2013525495A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
BR112012028321A2 (pt) "compostos análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes de quelação de metal, composição farmacêutica e usos dos ditos compostos"
MY163516A (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
PH12017501306A1 (en) Inhibitors of histone demethylases
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
BR112012009214A2 (pt) compostos
WO2011017054A3 (en) Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
PH12014501560A1 (en) Carbamate compounds and of making and using same
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
BR112014017780A8 (pt) Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
TW200611695A (en) Pyrrolopyridine derivatives
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
MX2023009856A (es) Dosificacion optimizada de diaminofenotiazinas en poblaciones.
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
MX2018010727A (es) Acido (2s,4r)-5-(5'-cloro-2'-fluoro-[1,1'-bifenil]-4-il)-2-(etoxim etil)-4-(3-hidroxiisoxazol-5-carboxamido)-2-metilpentanoico cristalino, y sus usos.
EA201200838A1 (ru) Средство для лечения болезни паркинсона
BR112013000296A2 (pt) agentes terapêuticos 976

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)